Pathological Outcomes for Patients Who Failed To Remain Under Active Surveillance for Low-risk Non–muscle-invasive Bladder Cancer: Update and Results from the Bladder Cancer Italian Active Surveillance Project

Millan-Rodriguez, 2000, Primary superficial bladder cancer risk groups according to progression, mortality and recurrence, J Urol, 164, 680, 10.1016/S0022-5347(05)67280-1 Rieken, 2014, Long-term cancer-specific outcomes of TaG1 urothelial carcinoma of the bladder, Eur Urol, 65, 201, 10.1016/j.eururo.2013.08.034 Sylvester, 2006, Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials, Eur Urol., 49, 466, 10.1016/j.eururo.2005.12.031 Brausi, 2002, Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies, Eur Urol, 41, 523, 10.1016/S0302-2838(02)00068-4 Soloway, 2003, Expectant management of small, recurrent, noninvasive papillary bladder tumours, J Urol, 170, 438, 10.1097/01.ju.0000076621.71247.6c Martinez Caceres, 2005, Is it necessary to always treat the relapses of superficial bladder tumour at the moment of diagnosis? Preliminary communication, Actas Urol Esp, 29, 567 Gofrit, 2006, Watchful waiting policy in recurrent Ta G1 bladder tumours, Eur Urol, 49, 303, 10.1016/j.eururo.2005.12.029 Pruthi, 2008, Conservative management of low risk superficial bladder tumours, J Urol, 179, 87, 10.1016/j.juro.2007.08.171 Hernandez, 2009, Safety of active surveillance program for recurrent non muscle-invasive bladder carcinoma, Urology, 73, 1306, 10.1016/j.urology.2008.12.061 Gofrit, 2008, Active surveillance of low grade bladder tumors, Arch Ital Urol Androl, 80, 132 de la Pena, 2013, Oncological safety of an active surveillance program in recurrent non muscle-invasive bladder tumour, J Urol, 189, e731 Lozano, 2014, Active surveillance in low risk bladder cancer. When TUR is recommended?, J Urol, 191, e569 Hernández, 2016, Long-term oncological outcomes of an active surveillance program in recurrent low grade Ta bladder cancer, Urol Oncol, 34, 10.1016/j.urolonc.2015.11.005 Hurle, 2018, Active surveillance for low risk nonmuscle invasive bladder cancer: a confirmatory and resource consumption study from the BIAS project, J Urol, 199, 401, 10.1016/j.juro.2017.08.091 Hurle, 2016, Active surveillance for low-risk non-muscle-invasive bladder cancer: mid-term results from the Bladder cancer Italian Active Surveillance (BIAS) project, BJU Int, 118, 935, 10.1111/bju.13536 Strock, 2013, A prospective study of size, number and histopathology of new and recurrent bladder tumors, Urol Pract, 2, 260, 10.1016/j.urpr.2015.03.002 Angulo, 1995, Muscularis mucosa differentiates two populations with different prognosis in stage T1 bladder cancer, Urology, 45, 47, 10.1016/S0090-4295(95)96490-8 2004 2009 During, 2016, Prediction of histological stage based on cystoscopic appearances of newly diagnosed bladder tumours, Ann R Coll Surg Engl, 98, 547, 10.1308/rcsann.2016.0246 Capogrosso, 2016, Detrusor muscle in TUR-derived bladder tumor specimens: can we actually improve the surgical quality?, J Endourol, 30, 400, 10.1089/end.2015.0591 Herr, 2001, Does cystoscopy correlate with the histology of recurrent papillary tumours of the bladder?, BJU Int, 88, 683, 10.1046/j.1464-4096.2001.02396.x Satoh, 2002, Prediction of muscle invasion of bladder cancer by cystoscopy, Eur Urol, 41, 178, 10.1016/S0302-2838(01)00035-5 Hurle, 2016, Impact of a teaching program on outcome quality of white light transurethral resection for bladder tumor: a cohort study, J Solid Tumors, 2, 56 Wedderburn, 1999, A prospective trial of flexible cystodiathermy for recurrent transitional cell carcinoma of the bladder, J Urol, 161, 812, 10.1016/S0022-5347(01)61778-6 Wong, 2013, Outpatient laser ablation of non-muscle-invasive bladder cancer: is it safe, tolerable and cost-effective?, BJU Int, 112, 561, 10.1111/bju.12216